Approximately 3–6 % of lung adenocarcinoma were shown to harbor rearrangements of the ALK gene, which has been demonstrated to be a potent oncogenic driver and a promising therapeutic target (Paik et al. 2011). The gene discussed is ALK; the disease is lung adenocarcinoma.